What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?

Current Opinion in Hematology

Volumn 23, Issue 2, 2016, Pages 121-126

  Mantha, Simon ^a   Tallman, Martin S ^a   Soff, Gerald A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

acute promyelocytic leukemia; disseminated intravascular coagulation; hemorrhage; hyperfibrinolysis

Indexed keywords

ARSENIC TRIOXIDE; BLOOD CLOTTING FACTOR; CYTOKINE; ELASTASE; LIPOCORTIN 2; PARACETAMOL; PLASMINOGEN ACTIVATOR; RETINOIC ACID; THROMBOMODULIN; THROMBOPLASTIN; ANTINEOPLASTIC AGENT;

BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; LEUKOCYTE COUNT; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY HYPERFIBRINOLYSIS; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; THROMBOCYTE COUNT; BLOOD; BLOOD CLOTTING; BLOOD COAGULATION DISORDERS; COMPLICATION; DRUG EFFECTS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MORTALITY; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROGNOSIS; REMISSION INDUCTION; THROMBOMODULIN; TREATMENT OUTCOME; TRETINOIN;

EID: 84957436324     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000221     Document Type: Review

References (57)

1. Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34-43.
2. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395-3402.
3. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108:689-695.
4. Mitrovic M, Suvajdzic N, Bogdanovic A, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol 2013; 30:478.
5. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-1028.
6. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alphapositive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-1021.
7. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94:1192-1200.
8. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103:1237-1243.
9. Lengfelder E, Haferlach C, Saussele S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009; 23:2248-2258.
10. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011; 25:1128-1134.
11. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248-1254.
12. Paulson K, Serebrin A, Lambert P, et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 2014; 166:660-666.
13. Rahme R, Thomas X, Recher C, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia 2014; 28:2422-2424.
14. Dally N, Hoffman R, Haddad N, et al. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res 2005; 116:109-114.
15. Kim DY, Lee JH, Lee JH, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res 2011; 35:152-158.
16. Tallman MS, Lefebvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2:1341-1350.
17. Lee HJ, Park HJ, Kim HW, Park SG. Comparison of laboratory characteristics between acute promyelocytic leukemia and other subtypes of acute myeloid leukemia with disseminated intravascular coagulation. Blood Res 2013; 48:250-253.
18. Takahashi H, Tatewaki W, Wada K, et al. Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Hematol 1990; 33:90-95.
19. Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92:143-151.
20. Koyama T, Hirosawa S, Kawamata N, et al. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994; 84:3001-3009.
21. Yan J, Wang K, Dong L, et al. PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association. Proc Natl Acad Sci USA 2010; 107:3716-3721.
22. Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001; 115:382-391.
23. Rodeghiero F, Mannucci PM, Vigano S, et al. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984; 63:965-969.
24. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156:24-36.
25. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86:1072-1081.
26. Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994-1004.
27. Liu Y, Wang Z, Jiang M, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res 2011; 35:879-884.
28. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269:21198-21203.
29. Stein E, McMahon B, Kwaan H, et al. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22:153-163.
30. Dombret H, Scrobohaci ML, Ghorra P, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7:2-9.
31. Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71:511-517.
32. Jardi M, Fabregas P, Sagarra-Tio M, et al. Characterization of plasminogen binding to NB4 promyelocytic cells using monoclonal antibodies against receptor-induced binding sites in cell-bound plasminogen. J Biomed Biotechnol 2012; 2012:984589.
33. Avvisati G, ten Cate JW, Sturk A, et al. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70:43-48.
34. Sakata Y, Murakami T, Noro A, et al. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77:1949-1957.
35. Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2010; 36:917-924.
36. Ma G, Liu F, Lv L, et al. Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol 2013; 92:645-652.
37. Kwaan HC, Rego EM, McMachon B, Weiss I. Thrombin generation and fibrinolytic activity in microparticles in acute promyelocytic leukemia [abstract]. Blood 2013; 122:3620.
38. Griffin JD, Rambaldi A, Vellenga E, et al. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood 1987; 70:1218-1221.
39. Cozzolino F, Torcia M, Miliani A, et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 1988; 84:240-250.
40. Madoiwa S, Tanaka H, Nagahama Y, et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res 2011; 127:349-355.
41. Oudijk EJ, Nieuwenhuis HK, Bos R, Fijnheer R. Elastase mediated fibrinolysis in acute promyelocytic leukemia. Thromb Haemost 2000; 83:906-908.
42. Mantha S, Goldman D, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era [abstract]. Blood 2014; 124:948.
43. Chang H, Kuo MC, Shih LY, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol 2012; 88:321-328.
44. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007; 78:213-219.
45. Higuchi T, Shimizu T, Mori H, et al. Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia. Hematol Oncol 1997; 15:209-217.
46. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96:1247-1253.
47. Cunningham I, Gee TS, Reich LM, et al. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989; 73:1116-1122.
48. Cordonnier C, Vernant JP, Brun B, et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55:18-25.
49. Rodeghiero F, Avvisati G, Castaman G, et al. Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75:2112-2117.
50. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82:3241-3249.
51. Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37:1004-1009.
52. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875-1891.
53. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Rev Cancer 2010; 10:775-783.
54. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543-553.
55. Ikezoe T, Yang J, Nishioka C, et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells. Exp Hematol 2012; 40:457-465.
56. Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol 2014; 100:27-37.
57. Matsushita T, Watanabe J, Honda G, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, postmarketing surveillance study cohort. Thromb Res 2014; 133:772-781.